Saxagliptin in the treatment of diabetes mellitus type 2: focus on the cardiovascular safety

• Alexander S. Ametov
• Prudnikova M.A.

Abstract

The purpose of this article is to describe the efficiency of selective and competitive inhibitor of dipeptidyl peptidase-4 saxagliptin and saxagliptin/metformin extended-release (XR) fixed-dose combination. This article presents results of the assessment of cardiovascular safety in large-scale clinical trials of saxagliptin (SAVOR, GENERATION, and Real World Evidence).

Keywords:saxagliptin, diabetes mellitus type 2, cardiovascular safety

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)